TNFRSF17 and Miyoshi myopathy: BCMA-targeted CAR-T cells have produced very promising results in phase I clinical trials in RR MM patients, with many reporting overall response rates (ORRs) of 64–88% in a difficult-to-treat patient cohort [86,87,88].